Skip to NavigationSkip to content

Sanofi's Troujeo beats insulin degludec in head-to-head study in type 2 diabetes

Published on 19/09/19 at 11:17am

Sanofi took the opportunity at the 55th annual European Association for the Study of Diabetes to present new data from the first randomised control study directly comparing its Toujeo product with insulin degludec (iDeg) in patients starting treatment with insulin for the first time to manage their type 2 diabetes.

In adult patients with type 2 diabetes and moderate-to-severe kidney impairment, the results of the study showed that Toujeo produced a 0.43% greater reduction in average blood sugar in patients with moderate-to-severe renal impairment throughout the 24-week study period compared to iDeg, with “similar rates of low blood sugar risk”.

Additionally, the same analysis revealed that a similar level of blood sugar control was observed in patients with normal kidney function from both treatments with lower rates of blood sugar.

“In patients with moderate-severe renal impairment, whose diabetes is often complex to manage, Gla-300 appears to confer glycaemic advantages versus IDeg, without compromising on hypoglycaemia, warranting further investigation,” commented Dr Martin Haluzik, Deputy Director, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, and an investigator of the study. “These results are consistent with another exploratory analysis from BRIGHT, in which Gla-300 greater reduction in blood sugar and similar rates of hypoglycaemia were seen when compared to iDeg in people aged 70 years or older.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches